Jump to content

Vasoprotective

From Wikipedia, the free encyclopedia
(Redirected from Vasoprotectives)

A vasoprotective is a medication which acts to alleviate or prevent conditions or diseases which affect the blood vessels. The term is used in the World Health Organization's Anatomical Therapeutic Chemical Classification System to encompass therapeutic agents used in the treatment of hemorrhoids or varicose veins.[1] The term may also be used to describe drugs which lower the risk of developing hypercholesterolemia or hypertension.[2]

Examples of vasoprotectives include 1-methylnicotinamide,[3] estrogen,[4] tribenoside,[5] and valsartan.[6] More specifically, arterial vasoprotectors are called angioprotectors.

See also

[edit]

References

[edit]
  1. ^ "ATC/DDD Index". WHO Collaborating Centre for Drug Statistics Methodology. 2019-12-16. Retrieved 2020-01-28.
  2. ^ Henry PD, Cabello OA (1995). "Vasoprotection and antihypertensive therapy". Curr Opin Nephrol Hypertens. 4 (2): 197–200. doi:10.1097/00041552-199503000-00014. PMID 7600051.
  3. ^ Domagala, T. B.; Szeffler, A.; Dobrucki, L. W.; Dropinski, J.; Polanski, S.; Leszczynska-Wiloch, M.; Kotula-Horowitz, K.; Wojciechowski, J.; Wojnowski, L.; Szczeklik, A.; Kalinowski, L. (2012). "Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels". Hypertension. 59 (4): 825–832. doi:10.1161/HYPERTENSIONAHA.111.183210. PMID 22353616. S2CID 302943.
  4. ^ Wassmann K, Wassmann S, Nickenig G (November 2005). "Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function". Circ. Res. 97 (10): 1046–54. doi:10.1161/01.RES.0000188212.57180.55. PMID 16195479.
  5. ^ Lorenc Z, Gökçe Ö (2016). "Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence". Eur Rev Med Pharmacol Sci. 20 (12): 2742–51. PMID 27383331.
  6. ^ Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M (September 2005). "Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression". Hypertension. 46 (3): 577–83. doi:10.1161/01.HYP.0000178564.14464.80. PMID 16103268.